---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-200159"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:01:19.688361+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch

## Summary
- Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.
- Proceeds to advance avexitide commercial readiness, R&D, working capital, and general corporate purposes.
- Underwriting led by Leerink Partners and Guggenheim Securities; expected closing September 11, 2025.
- Underwriters granted 30-day option to purchase up to 2.625M additional shares at offering price less discounts.

## SEC filing metadata
- accession: 0001193125-25-200159
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312525200159/0001193125-25-200159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312525200159/d947193d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-200159
- JSON: https://secwatch.observer/filing/0001193125-25-200159.json
- Plain text: https://secwatch.observer/filing/0001193125-25-200159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.